Company profile
NovaBridge Biosciences
NASDAQ: NBP · Healthcare · Biotechnology
#729 of 1,422 Healthcare companies by revenuebottom-decile growth
EA Score
36DFH 55DQ 17GM 8SS 48
v0.1 · 65/100 weight · provisional
↑ Altman-Z, balance-sheet leverage · ↓ filing timeliness, growth stability
Methodology →Revenue TTM
$3.9M
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$46.3M
Employees
30
as of 2026-08-13
Market cap
$215.5M
as of 2026-08-13
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$3.9M$3.9M2023
Net income-$46.3M-$46.3M2025
Operating income-$94.3M-$94.3M2025
Total assets$260.5M$260.5M2025
Liabilities$29.6M$29.6M2025
Equity$230.9M$230.9M2025
Revenue trend
FY2019 – FY2023 · USD
FY19
FY20
FY21
FY22
FY23
Revenue by segment
Filed disclosures · FY2023
By product
Licensing and Collaboration61%
Supply Of Investigational Products39%
By geography
Not disclosed.
The read
What is NovaBridge Biosciences’s revenue?
NovaBridge Biosciences booked $3.9M in FY2023 revenue, contracting 112% year over year — among the slowest-growing Healthcare companies we track, at a -1188.5% net margin.
Peers · Healthcare
CG Oncology Inc.47DCervoMed Inc.42DTenon Medical, Inc.35DTarget Group Inc.46DEVIO, Inc.——Cibus, Inc.43DNeighbors
Montgomery →Key facts
CEOSrishti Gupta
SectorHealthcare
IndustryBiotechnology
HeadquartersRockville, MD
ExchangeNASDAQ: NBP
Employees30
IPO date2020-01-17
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.